Latest News - Headache & Pain

Tuesday, February 20, 2018 | Headache & Pain

Migraine Sufferers May Be at Greater Risk of Ischemic Stroke

Stroke, a journal of the American Heart Association published an article by Alessandro Pezzine, Giorgio Busto, Marialuisa Zedde, et al., (Stroke. 2018:published online Feb 20) suggesting that migraine…

Read the full story

Thursday, January 25, 2018 | Clinical Trials, Headache & Pain

First Prospective Registry Shows Efficacy of Neuromodulation of the Sphenopalatine Ganglion for Treating Cluster Headache

On January 25, 2018, The Journal of Headache and Pain published one-year results from an open-label registry trial, Pathway R-1, evaluating the efficacy of sphenopalatine-ganglion stimulation (SPGs) (…

Read the full story

Monday, January 08, 2018 | Clinical Trials, Headache & Pain, Phase 3/4 Trials

PROMISE Phase 3 Trial for Chronic Migraine Prevention Meets Primary and All Key Secondary Endpoints; Shows Reduction in Migraine Risk

January 8, 2018--Alder Biopharmaceutical reported that their injectable calcitonin-gene-related peptide (CGRP)-inhibitor eptinezumab, in phase 3 clinical trials, reduced monthly migraine days by 50% o…

Read the full story

Thursday, October 12, 2017 | FDA Approval/Clearance, Headache & Pain, Phase 3/4 Trials, Research and Publications, Pfizer

Once-Daily Lyrica Formulation Wins FDA Approval

The FDA has approved Lyrica CR (pregabalin, Pfizer) extended-release tablets CV as once-daily therapy for the management of neuropathic pain associated with diabetic peripheral neuropathy (pDPN) and t…

Read the full story

Wednesday, September 20, 2017 | FDA Approval/Clearance, Headache & Pain, Product Launches and Updates

FDA Approves Intellis Device for Intractable Pain

The FDA has approved the Intellis platform (Medtronic) for the management of certain types of chronic intractable pain. The Intellis platform was designed to overcome limitations with current spinal c…

Read the full story

Tuesday, August 01, 2017 | FDA Approval/Clearance, Headache & Pain

Non-Invasive Neuromodulation Device for Chronic Intractable Pain Cleared by FDA

The FDA has cleared the Stimpod NMS460 (Xavant Technology), a non-invasive neuromodulation device for the symptomatic relief and management of chronic intractable pain. When applied to the affected ar…

Read the full story

Tuesday, June 13, 2017 | Headache & Pain, Phase 3/4 Trials, Research and Publications

AHS 2017: Amgen’s CGRP Inhibitor Reduces Migraine Days

New Phase 2 data show that Amgen’s investigational investigational CGRP inhibitor erenumab is effective at preventing migraine in patients experiencing 15 or more migraine days per month. In a s…

Read the full story

Thursday, June 08, 2017 | Headache & Pain, Phase 3/4 Trials, Research and Publications

AHS 2017 Meeting: Prochlorperazine More Effective than Hydromorphone for Acute Migraine

A new comparative study presented at the American Headache Society Annual Meeting in Boston shows that that, in patients who visit the emergency department for acute migraine treatment, prochorperazin…

Read the full story

Thursday, June 08, 2017 | Headache & Pain, Phase 3/4 Trials, Research and Publications

AHS 2017 Meeting: Non-Invasive Medical Devices Show Promise for Severe Headaches

Results from studies presented at the American Headache Society Annual Meeting in Boston suggest that non-invasive medical devices offer effective interventions for individuals with migraine. …

Read the full story

Thursday, June 01, 2017 | Headache & Pain, Phase 3/4 Trials, Research and Publications

Teva’s Fremanezumab Reduces Monthly Headache Days in Phase 3 Chronic Migraine Study

    Results from the Phase 3 HALO study suggest that fremanezumab (Teva Pharmaceuticals) reduces the number of monthly headache days in patients with chronic migraine. Fremanezumab is …

Read the full story

Friday, May 19, 2017 | Headache & Pain, Research and Publications

Migraine Prevalence Higher in Collegiate Athletes, New Study Finds

New findings suggest that collegiate athletes have an increased prevalence of migraines, with female athletes being particularly affected. In a retrospective cross-section survey, researchers evaluate…

Read the full story

Friday, May 12, 2017 | Headache & Pain, Phase 3/4 Trials, Research and Publications

Lilly’s Investigational Monoclonal Antibody for Migraine Scores Positive Phase 3 Results

New Phase 3 data suggest that Eli Lilly’s investigational monoclonal antibody galcanezumab may significantly reduce the number of monthly migraine headache days. In the EVOLVE-1 study, pati…

Read the full story

Tuesday, April 18, 2017 | FDA Approval/Clearance, Headache & Pain

FDA Releases Non-Invasive VNS Therapy for Pain Associated with Episodic Cluster Headache

The FDA has released the use of gammaCore, a non-invasive vagus nerve stimulator for the acute treatment of pain associated with episodic cluster headache in adult patients. gammaCore transmits a mild…

Read the full story

Thursday, March 30, 2017 | FDA Approval/Clearance, Headache & Pain

FDA Approves Expanded Indication For Qudexy XR Extended Release Capsules

The FDA has approved two supplemental indications for Qudexy XR (topiramate, Upsher-Smith) Extended Release Capsules for use as prophylaxis of migraine headache in adults and adolescents 12 years of a…

Read the full story

Friday, March 24, 2017 | Epilepsy & Seizure Disorders, Headache & Pain, Research and Publications

Review Identifies Antidepressants and AEDs Effective for Nerve Pain

A federal health agency has found certain antidepressants and anti-seizure drugs are among medications that effectively treat diabetic nerve pain. In findings published in the journal Neurology, resea…

Read the full story
Load More